Compounds > sorafenib
Page last updated: 2024-09-05

sorafenib and Tumor Lysis Syndrome

sorafenib has been researched along with Tumor Lysis Syndrome in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's1 (20.00)2.80

Authors

AuthorsStudies
Imam, SZ; Maqbool, MA; Zahid, MF1
Choi, HS; Hahm, JS; Jun, DW; Kim, JO; Lee, HL; Lee, KN; Lee, OY; Tae, HJ; Yoon, BC1
Huang, WS; Yang, CH1
Ichijo, T; Joshita, S; Kamijo, A; Kobayashi, S; Komatsu, M; Matsumoto, A; Morita, S; Sano, K; Sekiguchi, T; Tanaka, E; Umemura, T; Yoshizawa, K1
Abbass, K; Baumann, MA; Dewani, S; Kaplon, MK; Markert, R1

Other Studies

5 other study(ies) available for sorafenib and Tumor Lysis Syndrome

ArticleYear
Sorafenib-induced tumor lysis syndrome in a patient with metastatic hepatocellular carcinoma.
    Hematology/oncology and stem cell therapy, 2020, Volume: 13, Issue:3

    Topics: Carcinoma, Hepatocellular; Fatal Outcome; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Sorafenib; Tumor Lysis Syndrome

2020
Low-dose steroid-induced tumor lysis syndrome in a hepatocellular carcinoma patient.
    Clinical and molecular hepatology, 2015, Volume: 21, Issue:1

    Topics: Acute Kidney Injury; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Creatinine; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Sorafenib; Steroids; Tomography, X-Ray Computed; Tumor Lysis Syndrome

2015
Sorafenib induced tumor lysis syndrome in an advanced hepatocellular carcinoma patient.
    World journal of gastroenterology, 2009, Sep-21, Volume: 15, Issue:35

    Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Fatal Outcome; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Tumor Lysis Syndrome

2009
A patient with advanced hepatocellular carcinoma treated with sorafenib tosylate showed massive tumor lysis with avoidance of tumor lysis syndrome.
    Internal medicine (Tokyo, Japan), 2010, Volume: 49, Issue:11

    Topics: Adult; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Tumor Lysis Syndrome

2010
All that glitters: sorafenib.
    Internal medicine (Tokyo, Japan), 2011, Volume: 50, Issue:7

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Fatal Outcome; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Tumor Lysis Syndrome

2011